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Abstract 
Purpose: To study the suitability of injectable microspheres based on poly(ester 
amide) (PEA) or poly lactic-co-glycolic acid (PLGA) as potential vehicles for 
intravitreal drug delivery in rat eyes. Dexamethasone-loaded PEA microspheres 
(PEA+DEX) were also evaluated.  
Methods: Forty male Sprague Dawley rats were divided into four groups that 
received different intravitreally injected microspheres: PEA group (n=12); PLGA 
group (n=12); PEA+DEX group (n=8); and control group (no injection, n=8). 
Electroretinography (ERG), fundus autofluorescence (FAF), and spectral domain 
optical coherence tomography (sdOCT) were performed at baseline, weeks 1 and 2, 
and months 1, 2, and 3 after intravitreal injection. Eyes were histologically examined 
using light microscopy and transmission electron microscopy at the end of the in vivo 
study. 
Results: There were no statistically significant changes in ERG among the groups. 
Abnormal FAF pattern and abnormal deposits in OCT were observed after injection 
but almost completely disappeared between week 2 and month 3 in all injected 
groups. GFAP staining showed that Müller glia cell activation was most pronounced 
in PLGA-injected eyes. Increased cell death was not observed by TUNEL staining at 
month 1. In electron microscopy at month 3, the remnants of microparticles were 
found in the retinal cells of all injected groups, and loss of plasma membrane was 
seen in the PLGA group. 
Conclusions: Although morphological changes such as mild glial activation and 
material remnants were observed histologically 1 month and 3 months after injection 
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in all injected groups, minor cell damage was noted only in the PLGA group at 3 
months after injection. No evidence of functional abnormality relative to untreated 
eyes could be detected by ERG 3 months after injection in all groups. Changes 
observed in in vivo imaging such as OCT and FAF disappeared after 3 months in 
almost all cases. 
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Recently, sustained intraocular drug delivery systems have received great 
attention because they can release the drug over a long time with only a single 
administration, thus avoiding the requirement for repeated multiple injections to 
maintain therapeutic drug levels, through their ability to cross the blood-ocular barrier. 
Biodegradable polymers have the additional advantage of disappearing from the 
vitreous after releasing the drug [1]. Currently, among the biodegradable polymers 
used to prepare drug delivery systems, poly lactic-co-glycolic acid (PLGA, [2]) is 
most widely used for various vitreoretinal diseases such as age-related macular 
degeneration, diabetic macular edema, and uveitis [3-9]. Biodegradable 
polyesteramides are a new class of biomaterials that show promise for medical 
applications, including drug delivery [10]. Amino acid-based polyesteramides (PEAs) 
are a new family of biodegradable polymers based on alpha-amino acids, aliphatic 
dicarboxylic acids, and aliphatic α-ω diols [11]. Incorporation of amino acid-based 
building blocks not only provides metabolizable degradation products [10], but also 
offers one or more functional groups along the polymer chain. This allows further 
modification of the polymer to tailor its physicochemical properties, degradation 
properties [12,13], and performance as a drug eluting matrix. In addition to good 
biocompatibility properties [14], the PEA material platform offers novel attractive 
features of particular interest for drug delivery [15,16]. PEA polymers are well 
tolerated in vivo and can be easily processed to yield a variety of medical device 
coatings [17], micron-sized implants, and particles [16]. Additionally, the polymer 
backbone undergoes enzymatic degradation via a unique surface erosion 
mechanism that does not produce changes in local pH [1,18]. This class of polymers 
has recently been explored as a drug delivery vehicle in a variety of ophthalmologic 
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therapies. The current paper focuses on the tolerability of PEA microparticles in the 
eye vitreous. Particle biocompatibility is benchmarked versus medical grade PLGA – 
a biomaterial known for its good biocompatibility and degradability in physiological 
environments. In the present study, microspheres containing PEA, PLGA, and PEA 
plus dexamethasone (PEA+DEX) were administered intravitreally in addition to a no-
injection control, and all groups were assessed in terms of functional and 
morphologic alterations of the retina by electroretinography (ERG), in vivo imaging 
by fundus autofluorescence (FAF), spectral domain optical coherence tomography 
(sdOCT), and histology (immunohistochemistry, TUNEL assay, and transmission 
electron microscopy (TEM)) in the albino rat eye. 
Materials 
The PEA polymer in this work is random co-polymer comprising three di-amino 
building blocks randomly connected by di-acid to form the polymer chain and 
prepared by the Department of Pharmacy and Pharmaceutical Technology, Faculty 
of Pharmacy, Complutense University of Madrid, Spain. 
Polyesteramide (PEA III Ac Bz, Mn = 49 kDa, PDI =1,56, Tg = 49°; provided by DSM, 
Geleen, Netherlands) and Poly-(D,L-lactide-co-glycolide) Mn = 35 kDa (PLGA ratio 
50:50; Resomer® 503, Boehringer Ingelheim, Germany) microspheres were 
prepared based on the emulsion solvent-evaporation technique, as described in 
Andrés-Guerrero et al. [19,20]. Briefly, an organic phase composed of the polymer 
(PEA or PLGA) and dichloromethane (DCM) was emulsified (Polytron PT3000, 
Kinematica, Lucerna, Switzerland) with an aqueous solution of polyvinyl alcohol 67 
kDa (PVA; Merck (Darmstadt, Germany). Then, the resulting emulsion was kept 
under constant stirring to allow organic solvent evaporation and hardening of 
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microspheres. In a final step, microspheres were washed, filtered and freeze-dried to 
obtain solid microspheres. To prepare drug-loaded microspheres, dexamethasone 
(DX) was dispersed in an organic phase composed by PEA and DCM at a ratio 2:10, 
followed by the rest of the steps described for the formation of non-loaded 
microspheres.  
Microspheres were imaged through scanning electron microscopy to visualize their 
ultrastructure (SEM; Jeol JSM-6335F, Tokyo, Japan). Mean particle size and particle 
size distribution were measured by light scattering in a Microtrac S3500 Series 
Particle Size Analyzer (Montgomeryville, PA, USA). Data are presented as mean 
volume diameter ± standard deviation of three independent measurements. 
The encapsulation efficiency of DX in PEA microspheres and the in vitro release 
studies of solid DX-PEA Microspheres were determined by high performance liquid 
chromatography (HPLC; Pump M520, UV detector M490E, autosampler 712D 
WTSP and the Empower Login HPLC System Manager Software), as previously 
described [19]. The method was validated with respect to linearity, accuracy and 
reliability in the range of concentrations of 2-20 µg/mL, for both the evaluation of the 
encapsulation efficiency (determined in a mixture of DCM/ACN) and the in vitro 
release study (performed in release media). Succinctly, to analyze drug content, 5 
mg of DX loaded PEA microspheres were dissolved in DCM (0.2 mL) and diluted in 
ACN (0.8 mL), followed by a centrifugation (15,000 rpm, 4ºC, 15 min) and filtration 
(0.45 µm membrane) process. For the in vitro release studies, 5 mg of solid DX-PEA 
microspheres were incubated in a phosphate buffered solution isotonized with 
sodium chloride (PBS, pH 7.4) under sink conditions. Samples were placed in a 
water bath at 37ºC, being constantly shacked (100 rpm). At pre-set times (1h, 24h 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 



and twice every week during 90 days) the supernatant was collected and analyzed 
by HPLC as described below (the study was performed in triplicate).  
Microspheres characterization 
The preparation process yielded round microspheres with smooth surface. Mean 
particle size of microspheres ranged between 10 to 20 µm (13.1 ± 7.1 µm for blank 
PEA microspheres, 14.9 ± 6.4 µm for DX-loaded PEA microspheres and 19.2 ± 6.1 
µm for PLGA microspheres), optimum to be administered as an aqueous suspension 
by intravitreal injection through standard needles (27-34G) (Supplementary Fig. 1). 
The encapsulation efficiency of DX was around 85% (181.2 ± 2.4 µg DX/mg 
microspheres, respectively). DX-loaded PEA microspheres are capable of providing 
a sustained release of DX for at least 90 days. The release was characterized by an 
initial burst of 17.3 ± 0.4 µg DX/mg microspheres (9.4 ± 0.3%) during the first 24 h, 
followed by a short rapid release period of one week and a second long period of 
slow release up to 90 days. The cumulative release of the drug was around 54.4% of 
the encapsulated active substance (99.5 µg DX/mg Microspheres) at the end of the 
release assay (day 90). The degradation properties of PEA III Ac Bz are described 
previously [11,14,21,23] 
Methods  
Forty male Sprague Dawley rats (age: 15–16 weeks, breeder: Charles River 
Laboratories Inc., Sulzfeld, Germany) with a mean weight ± standard deviation (SD) 
of 301.78 ± 22.52 g at baseline were included. The animals were divided into four 
groups according to the intravitreally injected drug material: PEA group (n = 12); 
PLGA group (n = 12); PEA+DEX group (n = 8); control group (n = 8). Sterile 
microspheres suspended in 3 µl of sterile balanced salt solution (BSS; 25 mg/ml) 
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were injected via the pars plana of the right eye under a surgical microscope; the left 
eye did not receive any treatment and served as a control in functional analyses 
(ERG). For the PEA+DEX group, PEA microspheres were loaded with 
dexamethasone (181.0 ± 2.4 µg dexamethasone/mg PEA microspheres). The 
highest possible dexamethasone dose in the microsphere injection was 
approximately 13.6 µg (181 µg/mg * 25 mg/ml * 0.003 ml). The control group did not 
receive intravitreal injection in either eye. The microspheres were slowly injected for 
30 seconds, and the elapsed time between injection and needle withdrawal from the 
eye was 30 seconds. All procedures and examinations were performed after 
intraperitoneal anesthesia with ketamine (100 mg/kg) and xylazine (5 mg/kg). ERG, 
FAF, and sdOCT were performed at six time points: 1 week before injection 
(baseline) and 1 week, 2 weeks, 1 month, 2 months, and 3 months after injection. 
Rats were sacrificed at month 1 for immunohistochemical and TUNEL staining (four 
rats each in the PEA and PLGA groups, two rats each in the PEA+DEX and control 
groups). Additionally, two rats of each group were sacrificed for TEM at month 3. The 
rats were housed under standard laboratory conditions with a 12-hour dark and light 
cycle under room illumination of intensity 25–70 lux at cage roof level and with free 
access to food and water. This study was approved by the Ethics Committee for 
Animal Research of the local authorities, and all procedures were performed 
according to institutional guidelines, European Union regulations for the use of 
animals in research, and the Association for Research in Vision and Ophthalmology 
Statement for the Use of Animals in Ophthalmic and Vision Research. 
 
Electroretinography 
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ERGs were recorded using an Espion e2 electrophysiology system and a 
Ganzfeld stimulator Color Dome (Diagnosys LLC Inc., Middleton, USA). All ERGs 
were recorded after 12 hours of dark adaptation. The pupils were dilated using one 
drop of 0.5% tropicamide (Mydriatikum®, Stulln, Germany) 20 minutes before ERG 
measurement, and a heating plate kept the body temperature at approximately 38°C. 
Subcutaneous platinum needles served as a ground electrode in the tail and as a 
reference electrode placed in the forehead between the eyes; active electrodes were 
gold ring electrodes placed on the cornea, which was moistened with 2% 
methylcellulose. Impedances of the electrodes were measured at 25 Hz before the 
start of the test and were kept below 10 kOhm during the recording. Signals were 
filtered digitally using a band pass filter (0.3 to 300 Hz). The dark-adapted (scotopic) 
ERG protocol consisted of eight steps with increasing luminance of white flashes at 
6,500 K (0.0001, 0.001, 0.01, 0.1, 1.0, 3.0, 10, and 100 cd.s/m2) and 4 ms duration. 
Oscillatory potentials (OP) were derived from the response to 10.0 cd.s/m² by 
bandpass filtering between 75 and 300 Hz. All scotopic flashes were delivered 
without background illumination and with a constant interstimulus interval of 10 s for 
dim flashes and up to 45 s for bright flashes, starting at 0.1 cd.s/m², to ensure stable 
dark-adapted conditions. Responses were averaged to increase the stimulus-to-
noise ratio (six times for dim flashes and two times for bright flashes). 
The photopic ERG protocol consisted of an initial light adaptation phase for 5 
minutes with background illumination of 34 cd/m2 that was kept on during all single-
flash and flicker stimuli. For single-flash response, two steps with 3 cd.s/m² and 30 
cd.s/m2 with 4 ms duration of single white flashes were chosen. Four flicker steps (5, 
10, 15, 20 Hz) were applied with constant white flashes of 3 cd.s/m2. An average of 
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two sweeps for single flashes and 30 sweeps for flicker stimulation were acquired. 
(Fig. 1). 
 
Figure 1. ERG response of healthy rat eye (OD) at baseline. Dark adapted a- and b- 
wave responses to eight flashes of increasing stimulus strength (0.0001–100 
cd.s/m2), oscillatory potentials, light-adapted cone response, and light-adapted cone 
flicker responses to four steps of increasing stimulus frequency (5–20 Hz). 
 
In vivo retinal imaging 
FAF and sdOCT were performed with a commercially available HRA+OCT 
Spectralis® device (Heidelberg Engineering Inc., Heidelberg, Germany) after ERG 
measurements. For adaptation to the optical qualities of the rat eye, a customized 
+3.25 diopter contact lens was used in front of the cornea. FAF and sdOCT images 
were acquired serially. The FAF images were acquired in both 30° and 55° field-of-

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view. The FAF image resolution was 1,536 x 1,536 pixels, and a wavelength of 488 
nm was used for excitation. Spectral domain OCT images included line, ring, and 
volume scans at 30° field-of-view. The number of A- scans per B-scan was 1,536. 
Optical depth resolution was approximately 7 µm, with digital resolution reaching 3.5 
µm. The line scan was performed horizontally and vertically. The volume scan was 
performed with 31 B-scans. To obtain a high-quality mean image, up to 100 frames 
were averaged using the inbuilt automatic real-time (ART) algorithm. 
 
Histology 
Immunostaining for GFAP (gliofibrillary acidic protein, a major constituent of the 
astrocyte cytoskeleton) and IBA-1 (microglia/macrophage-specific ionized calcium-
binding protein), terminal deoxynucleotidyl transferase dUTP nick end labeling 
(TUNEL) assay, and DAPI (4', 6-diamidino-2-phenylindole dihydrochloride) staining 
were performed in both eyes at month 1 (four rats in PEA and PLGA group, and two 
rats PEA+DEXA and control group). Eyes of two animals of each group were 
examined by TEM at month 3. After washing and embedding in tissue-freezing 
medium, eyecups were immediately fixed in 4% paraformaldehyde, frozen in liquid 
nitrogen, and cut in 12-µm serial sections. Detailed methods for tissue preparation, 
immunohistochemistry, TUNEL assay, and TEM are provided in the supplementary 
information. 
 
Data analysis and statistics 
Electrophysiological recordings were exported and pre-processed for 
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statistical analysis using ERG Explorer [24, 25]. Statistical analysis was performed 
using JMP® software (version 11.2.0 SAS institute, Cary, NC, USA). A two-way 
repeated analysis of variance (ANOVA) was conducted to compare the main effects 
of group and time on the electrophysiological responses. Group included four levels 
(PEA, PLGA, PEA+DEX, control), and time consisted of six levels (baseline, week 1, 
week 2, month 1, month 2, month 3). To reduce the influence of factors not related to 
the study question, such as interindividual differences and ERG measurement 
variability between different time points, statistical analysis was performed on the 
amplitude ratio (OD/OS) and on the implicit time (IT) difference (OD-OS), and each 
variable was compared to its own baseline. To compare oscillatory potentials (OP), 
the area under the curve (AUC) ratio (OD/OS) was measured. For analysis of the 
influence of different materials on the electrophysiological function of the retina, the 
following parameters were included in statistical analysis: dark-adapted single-flash 
responses at 0.001, 0.01, 3.0, 10, and 100 cd.s/m², dark-adapted OP at 10.0 cd.s/m², 
and light-adapted flicker response to 5, 10, 15, and 20 Hz. The selection of these 
parameters was determined with a focus on covering different subsystems of the 
retina: purely rod function (0.001 and 0.1 cd.s/m²), mixed rod-cone function (3.0, 10, 
and 100 cd.s/m²), purely cone function (light adapted flicker response), and function 
of inner retina (dark adapted oscillatory potentials). Multimodal mapper (MMM) 
software (Institute for Ophthalmic Research, University of Tuebingen, Tuebingen, 
Germany) [26] was used to quantify mean retinal thickness in ring scans of OCT. To 
acquire peripapillary retinal thickness (PRT) between the internal limiting membrane 
(ILM) and upper border of the retinal pigment epithelium (RPE) in the ring scan, the 
inner and outer borders were manually defined. The thickness at 38 equally spaced 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 



points was measured automatically in the MMM software. Mean PRT was compared 
between the preinjection and postinjection periods. P values < 0.05 were considered 
statistically significant. 
  
Results  
None of the animals showed any signs of systemic adverse events or 
impairment over the course of the study. Weight gain during the study was in the 
normal range [27,28]. A total of 11 of 32 injected eyes developed localized posterior 
capsular opacity (cataract) along the injection needle direction (PEA group = 4/12, 
PLGA group = 5/12, PEA+DEX group = 2/8, Control group = N/A). One rat 
developed a retinal detachment after intravitreal injection. Three animals died in the 
course of the study for reasons not related to the treatment or any procedure (two 
rats developed pneumonia, and one rat did not recover from anesthesia). 
 
Full-field electroretinography 
No difference was found among the four groups in dark- or light-adapted 
ERG responses (amplitude ratio or implicit time difference) for all time points relative 
to baseline. There were no significant differences among the groups or in the 
interaction between time point and group, except the effects of the time factor on b-
wave amplitude ratio (0.001 cd.s/m², p = 0.008) (Fig. 2A) and on b-wave implicit time 
difference (100 cd.s/m², p = 0.034) (Supplementary Fig. 2, Table 1). The b-wave 
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amplitude ratio and implicit time difference (dark-adapted 0.001 cd.s/m²) are shown 
in Figures 2A and 2B. The a-wave amplitude ratio and implicit time difference (dark-
adapted 3.0 cd.s/m²) are shown in Figures 2C and 2D. The b-wave amplitude ratio 
and implicit time difference (dark-adapted 3.0 cd.s/m²) are shown in Figures 2E and 
2F. The OP AUC ratio (10.0 cd.s/m²) for inner retina response is shown in Figure 2G. 
The 15 Hz flicker response (3.0 cd.s/m²) for light-adapted cone response is shown in 
Figure 2H. 
 
Figure 2. In the rod response to 0.001 cd.s/m², there was a significant effect of the 
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time factor in b-wave amplitude ratio (OD/OS) (p=0.008) (A) but not in b-wave 
implicit time difference (OD-OS) (B). In the rod-cone response to 3.0 cd.s/m², there 
was no significant effect of time or group in either a- or b-wave amplitude ratio 
(OD/OS) or implicit time difference (OD-OS) (C, D, E, F). In the rod-cone response to 
10.0 cd.s/m², there was no significant effect of time or group on oscillatory potentials 
AUC ratio (OD/OS) (G). In the 15 Hz flicker response to 3.0 cd.s/m², there was no 
significant effect of time or group on amplitude ratio (OD/OS) (H). 
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Table 1. P values of amplitude ratio (OD/OS) and implicit time difference (OD-OS) 
response to light stimuli. All analyses included all time points using a two-way 
repeated measure analysis of variance (ANOVA) with within factor time and between 
factor groups. 
 
 a-wave b-wave 
Dark-adapted 
single-flash 
response 
Amp ratio IT diff Amp ratio IT diff 
0.001 cd.s/m² N/A N/A 0.008 N/  
0.01 cd.s/m² N/A N/A N/S N/S 
3.0 cd.s/m² N/S N/S N/S N/S 
10 cd.s/m² N/S N/S N/S N/S 
100 cd.s/m² N/S N/S N/S 0.034 
Oscillatory potentials area under the curve ratio 
10.0 cd.s/m² N/S 
Light-adapted flicker response (amplitude ratio) 
5 Hz N/S 
10 Hz N/S 
15 Hz N/S 
20 Hz N/S 
Amp ratio = amplitude ratio; IT diff = implicit time difference; N/A = not applicable; 
N/S = not significant 
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In vivo retinal imaging 
In vivo retinal imaging was hampered in a relatively large number of animals 
due to cataract and retinal detachment. Abnormal FAF finding was detected after 
intravitreal injection in 5/8 eyes in PEA group, 5/7 eyes in PLGA group, and 5/5 eyes 
in PEA+DEXA group. Abnormal FAF patterns were ring, patch, or mottled patterns 
(Table 2).  
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Table 2. Fundus autofluorescence findings 
  Abnormal FAF pattern OCT 
 Group 
(number*) 
Patch 
(Fig. 4) 
Mottled 
(Fig. 5) 
Ring 
(Fig. 6) 
Abnormal 
deposit 
PEA group 
(n=8) 3 0 2 4 
PLGA group 
(n=7) 2 1 2 4 
PEA+DEX group 
(n=5) 0 3 2 5 
Control group 
(n=7) 0 0 0 0 
FAF = fundus autofluorescence; OCT = optical coherence tomography; PEA = poly 
(ester amide) based on α-amino acids, aliphatic dicarboxylic acids and aliphatic α-ω 
diols; PLGA = poly (lactic-co-glycolic acid); PEA+DEX = PEA plus dexamethasone.  
* the available number of images was decreased due to cataract, retinal detachment, 
or death during follow-up. 
 
Some animals developed abnormally increased FAF lesions in a circular 
pattern around the optic nerve (ring pattern) after intravitreal injection; this was most 
prominent at week 1 after injection, after which the intensity of abnormal FAF 
decreased. At the month 3 examination, the lesions had recovered or almost 
disappeared, and either very weak abnormal autofluorescence (AF) persisted or the 
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AF changed to a very subtle mottled pattern in 2/4 eyes in PEA group, 1/5 eyes in 
PLGA group, and 4/4 eyes in PEA+DEXA group (Figs. 3A, 4A, 5A, 6).  
 
 
Figure 3. PEA-injected eye (rat number 6). (A) Fundus autofluorescence (AF) image 
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showed a patch pattern of hyper-AF areas at week 1 after intravitreal injection. The 
lesions gradually decreased and almost disappeared with time, but some remaining 
abnormal AF changes were still noted at month 3. (B) Optical coherence tomography 
image demonstrated abnormal linear deposit (red circle) proximal to the 
photoreceptor inner segment and outer segment (IS/OS) junction at week 1 after 
intravitreal injection. The IS/OS junction was discernible from the deposit. At week 2, 
the lesion had disappeared, and the normal retinal layer was visible again. By month 
2, the retinal structure was intact. 
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Figure 4. PLGA-injected eye (rat number 23). (A) Fundus autofluorescence (AF) 
image showed a mottled pattern of hyper-AF around the optic disc at week 1 after 
intravitreal injection. The lesion gradually decreased and disappeared by month 3. (B) 
At week 1 after intravitreal injection, optical coherence tomography image 
demonstrated abnormal linear deposit (red circle) proximal to the photoreceptor inner 
segment and outer segment junction, and the outer segment layer of photoreceptor 
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could not be differentiated from the deposit. At week 2, the lesion disappeared, and 
the normal retinal layer began to be visible again. By month 2, the retinal structure 
was intact. 
 
Figure 5. PEA+DEX injected eye (rat number 29). (A) Fundus autofluorescence (AF) 
image showed a ring pattern of hyper-AF around the optic disc from week 1 after 
intravitreal injection. The lesion gradually decreased and almost disappeared with 
time, but some remaining weak hyper-AF changes were still noted at month 3. (B) 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 



Optical coherence tomography image demonstrated abnormal deposit (red circle) in 
the outer nuclear layer at week 1 after intravitreal injection. At week 2, the deposit 
had not disappeared. At month 3, the deposit was greatly decreased, and the intact 
retinal layer was appearing again even though minor deposits remained. 
 
 
Figure 6. Change in fundus autofluorescence (AF) grade with time (Grade 0 = no 
abnormal AF, 1 = mild change, 2 = moderate, 3 = severe, 4 = very severe abnormal 
AF). Splines are fitted to indicate the trend in the data. 
 
 
In the OCT image, abnormal linear deposits were noted over the 
photoreceptor inner segment and outer segment (IS/OS) junction or in the outer 
nuclear layer at week 1 after intravitreal injection. The IS/OS junction could be 
discerned from the deposit in some cases, while the outer segment layer of the 
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photoreceptor could not be separately differentiated from the deposit in the other 
cases. The lesion disappeared and the normal retinal layer was visible again in most 
cases at week 2, although minor retinal deposits remained inside the inner retina 
until month 3 (Figs. 3B, 4B, 5B). We could not find any significant change in PRT 
(Fig. 7). 
 
Figure 7. Change in peripapillary retinal thickness change (optical coherence 
tomography ring scan) with regression lines to indicate the trend in the data. 
 
Histology 
In 18 of 24 injected eyes examined, positive IBA-1 staining indicated 
microglial activation (Table 3).  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 



Table 3. Overview of histopathological findings and immunohistochemical staining, 
(x/y = x of y animals) 
  
TUNEL 
positive 
GFAP positive,  
up to axons 
IBA positive,  
reaching inner retina 
Right eye (injected)  
PEA 1/9 8/9 7/9 
PLGA 0/10 8/10 8/10 
PEA+DEX 0/5 4/5 3/5 
Control 0/5 1/5 0/5 
Left eye (control)  
PEA 0/9 1/9 1/9 
PLGA 0/10 2/10 0/10 
PEA+DEX 0/5 1/5 1/5 
Control 0/5 1/5 0/5 
TUNEL = terminal deoxynucleotidyl transferase dUTP nick end labeling; GFAP = 
anti-glial fibrillary acidic protein; IBA = anti-ionized calcium binding adapter molecule 
1; PEA = poly (ester amide) based on α-amino acids, aliphatic dicarboxylic acids and 
aliphatic α-ω diols; PLGA = poly (lactic-co-glycolic acid); PEA+DEX = PEA plus 
dexamethasone. 
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The PEA+DEX-injected eyes showed lower activation of microglial cells than 
did the PEA- or PLGA-injected eyes. In GFAP staining, Müller glia cell activation was 
seen in 20 of 24 injected eyes, but also in two non-injected eyes. Müller cell 
activation was more pronounced in PLGA-injected eyes and less pronounced in 
PEA-injected eyes. TUNEL staining showed no increase in cell death for all eyes 
examined. Particles were distributed all over the retina, mostly on the surface of the 
ILM, although some particles were also seen in the inner retina up to the RPE layer 
(Fig. 8). 
 
Figure 8. In immunohistochemical analysis at month 1, very prominent GFAP 
staining of Müller cells (green color) through the whole retina (from the ganglion cell 
layer [GCL] to external limiting membrane) was seen in the PLGA-injected eyes. In 
PEA+DEX-injected eyes, staining of GFAP was restricted to the Müller cell end feet 
and the GCL. In IBA staining, the PEA+DEXA-injected eyes showed milder activation 
of microglia than PEA- or PLGA-injected eyes. Microsphere particles were seen as 
red dots in GFAP and IBA staining. There was no TUNEL-positive staining that 
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would indicate increased cell death. 
 
Transmission electron microscopy 
TEM imaging performed in the right eye of two animals of each injected 
group at month 3 showed that the majority of microsphere particles were degraded. 
Remnants of degradation products of PEA were occasionally found in the basolateral 
space between RPE cells, basal labyrinth of RPE cells, blood vessels, and ganglion 
cells (Figs. 9A & 9B). In PLGA-injected eyes, degradation debris of PLGA was found 
in retinal cells, and loss of plasma membrane between two adjacent cells was 
observed (Figs. 9C & 9D).  
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Figure 9. TEM imaging at month 3. In PEA-injected eyes (A, B), the basolateral 
spaces between retinal pigment epithelial (RPE) cells were enlarged and contained 
membranous materials (arrows) that were probably degradation products of PEA, as 
shown in an overview (A) and in detail (B). The RPE cell nucleus is indicated with N. 
The cytoplasm of RPE cells is marked by asterisks. In PLGA-injected eyes (C, D), 
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degradation products of PLGA were present in retinal ganglion cells (arrows). The 
plasma membrane between two adjacent cells was missing (arrowhead), indicating 
cell damage (C). The frame in C is shown at higher magnification in D. The 
degradation remnants of PLGA are marked by an arrow. The fixation was good 
because the neurotubles in the axons were very well preserved and could be clearly 
discriminated (white arrow) (D). In PEA+DEX-injected eyes (E, F), the remnants of 
PEA+DEX (arrows) were localized within retinal cells, and a macrophage (arrowhead) 
was visible in the vitreous close to the inner limiting membrane (E). The surface of 
these macrophages had many pseudopodia indicating activation, possibly induced 
by dexamethasone. Residual material of PEA+DEX (white arrow) is shown in a RPE 
cell (F). Bruch’s membrane is labeled by an arrow. 
 
Discussion 
In the present study, three kinds of microspheres (PEA, PLGA, and 
PEA+DEX) were injected intravitreally, and their effects on eyes were compared with 
eyes of a control group using morphologic and functional examinations (OCT, FAF, 
ERG, and histology). None of the injected groups exhibited any signs of irreversible 
toxic effects over the course of the study. Rats were dosed intravitreally with 3 µl of 
microspheres at a given concentration of 5mg/mL, which was the most appropriate 
volume of PEA microspheres for intravitreal injection in the rat vitreous humor 
without increasing intraocular pressure. 
 
Full-field electroretinography 
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In the present study, we did not find any statistically significant effect of time, 
group, or interaction between these two factors, indicating that the injected material 
did not lead to any changes in ERG amplitudes or implicit times in rod-only, rod-cone, 
or cone-only responses, with the exception of the b-wave amplitude ratio (OD/OS) 
response to 0.001 cd.s/m² and the b-wave implicit time difference (OD-OS) response 
to 100 cd.s/m2. The absolute change in comparison of right (treated) and left (non-
treated) eyes was less than 20% for the b-wave amplitude ratio (OD/OS) response to 
0.001 cd.s/m² and less than 3% for the b-wave implicit time difference (OD-OS) 
response to 100 cd.s/m2 and therefore of no clinical relevance [29]. The number of 
parameters included in the statistical analysis (Table 1) with an alpha value of 0.05 
indicates that these findings are most possibly attributed to a type I error. An 
alternative explanation could be the transient influence of the intravitreal injection 
itself. These time/amplitude differences were mostly generated by a slight increase in 
implicit time of about 2 ms or decreased amplitude in an already very flat b-wave for 
the given stimulus of 0.001 cd.s/m² for the measuring points of week 1 and week 2 
and were consistent in most of the groups. However, this change does not indicate 
any irreversible functional impairment and was not consistent through other ERG 
parameters; therefore, a long-term damage effect cannot be assumed. 
In vivo retinal imaging 
Hyper-FAF changes were often found in a circular arrangement around the 
optic nerve head or in a patch or mottled fashion across the posterior pole. These 
deposits were located in the outer nuclear layer along the IS/OS junction and 
sometimes reached the outer segment layer in the OCT. The FAF changes became 
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weaker within 12 weeks and disappeared after 3 months, although subtle FAF 
changes remained in 2/4 eyes in the PEA group, 1/5 eyes in the PLGA group, and 
4/4 eyes in the PEA+DEXA group. The circular pattern may be caused by the 
preference for transporting very small particles or parts of particles along optic nerve 
fibers in the direction of the optic nerve head in the process of degradation. We 
propose that the hyper-AF in FAF imaging and the hyper-reflective signal in OCT 
were caused by deposits rather than by tissue damage. Andrés-Guerrero et al. 
reported that, under fluorescence microscopy equipped with filters for fluorescence-
emission spectra of 515/65 nm, 647/70 nm, and 445/45 nm, PEA microspheres had 
AF emission in the blue, green, and red spectral regions, respectively [19]. The 
PLGA microcapsules were found to have weak emission between 500 and 550 nm 
under excitation of 488 nm [30]. As the HRA+OCT Spectralis® device used in the 
present study employed a 488 nm laser for excitation and detected emitted light 
above 500 nm with a barrier filter for FAF, the device also might detect the AF from 
deposited material. Furthermore, most OCT abnormalities disappeared within 2 
weeks, and a normal intact retinal layer reappeared as soon as these abnormalities 
disappeared. There was no swelling, atrophy, disappearance, or disruption of the 
retinal layer at month 3; therefore, it can be concluded that no damage occurred. In 
the ring scan of OCT, we did not notice a significant change of retinal thickness in 
any group. 
Histology 
PEA microspheres can lose their shape or dissolve when in contact with 
xylene, ethanol, or acetone during the dehydration steps required for paraffin and 
epoxy resin embedding techniques [19]. Ethanol has also been found to change the 
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surface, pore size, and structure of PLGA [31]. The in-vitro degradation in PBS is 
very slow when the polymer degrades in presence of enzymes. In vivo degradation 
of the polymer does not match the in-vitro rate [11,14,20,21,23]. For histologic 
preparation in this study, the eyes were fixed in paraformaldehyde (for light 
microscopy) and glutaraldehyde (for electron microscopy), as described by Andrés-
Guerrero et al., and cryosectioned for tissue preparation for immunohistochemistry. 
Microsphere particles were seen as red dots in GFAP and IBA staining. In TEM, 
degradation remnants and empty spaces were observed inside and between retinal 
cells. Compared with the mean particle sizes of PEA (10–20 µm) and PLGA (20 µm) 
[19], the remnants of materials and empty spaces inside or between cells were very 
small (about 2–3 µm) and did not affect the viability of retinal cells. Activated 
macrophages detected in the vitreous space near the inner limiting membrane (ILM) 
might be associated with the degradation of material. The empty space in TEM might 
be caused in part by washout effects of material by ethanol during the dehydration 
steps for tissue preparation. The PLGA group showed more pronounced Müller cell 
activation than the other groups in immunohistochemistry at 1 month and greater 
loss of the plasma membrane between two adjacent cells in TEM at 3 months. 
These findings in immunohistochemistry and TEM could imply cellular damage even 
though there was no sign of increased cell death in TUNEL staining or significant 
functional changes in ERG. The PEA microspheres loaded with dexamethasone 
showed less pronounced Müller cell and microglial cell activation in both GFAP and 
IBA staining, indicating the protective effect of dexamethasone. Glial cell activation is 
a quite common reaction to intravitreal injection itself [32,33,34,35]. Müller cells are 
important for preserving normal retinal function and protect the tissue from injuries 
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[36]. Similar to Müller cells, the reactivation of astrocytes (astrogliosis) also occurs in 
response to nervous system damage [37]. Reactive gliosis includes morphological, 
biochemical, and physiological changes of Müller cells [32,39]. An important 
mechanism is increased expression of the intermediate filaments GFAP, vimentin, 
and nestin, which is a crucial step for the gliotic response [35,38]. Such changes do 
not necessarily indicate pathology but may represent a physiological response that 
does not indicate toxicological events. However, gliosis is also associated with 
functional changes in Müller cell such as glycolysis, potassium flow, and water 
clearance, which result in edema and neuron hyperexcitability caused by glutamate 
toxicity [32,36,40,41]. In gliosis the potassium extraction of Müller cell membranes 
decreases dramatically [40], which would change the ERG responses. In the present 
study, no significant change was observed in the ERG response, implying that no 
dramatic change in potassium extraction [40] occurred in Müller cells. Moreover, the 
FAF change and OCT deposits tended to disappear by month 3, which suggested a 
reversible non-toxic effect. This was also supported by the lack of swelling in OCT 
and histology results indicating that no glutamate toxicity occurred [32,36,40,41].  
In summary, prominent adverse effects were not detected 3 months after 
intravitreal injection of microspheres compared to untreated eyes. Although hyper-
FAF and abnormal deposits were detected in the FAF and OCT images, most 
changes were resolved at month 3, and there was no significant change in rod or 
cone amplitude or implicit times in ERG. TEM imaging showed that the majority of 
microsphere particles were degraded, leaving tiny remnants or empty spaces in the 
retinal and RPE cells or basolateral space between RPE cells in all injected groups, 
although minor cell damage was observed in the PLGA group at month 3. Further 
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studies with a longer period of observation, dose escalation, different microsphere 
sizes, and different sites of injection (e.g., intravitreal vs. subretinal vs. 
suprachoroidal) will be needed to ascertain the safety of these drugs. 
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